Search jobs 15-Apr-2021 HUMMINGBIRD BIOSCIENCE PRESENTS PRE-CLINICAL DATA ON ITS NEXT-GENERATION BCMA-TACI DUAL-SPECIFIC T CELL ENGAGER AT 2021 AACR ANNUAL MEETING HUMMINGBIRD BIOSCIENCE 2021 AACR ANNUAL MEETING
Singapore, April 10, 2021 – Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced that the company will be presenting pre-clinical data on its BCMA-TACI dual-specific T cell engager, HMBD-009, at the 2021 American Association for Cancer Research (AACR) Annual Meeting taking place 9-14 April. HMBD-009 is Hummingbird’s next-generation T cell program that uniquely targets both B cell maturation antigen (BCMA) and Transmembrane activator and CAML Interactor (TACI), proteins commonly overexpressed in multiple myeloma, the second most common hematologic malignancy and a leading cause of cancer deaths in the US